Issue link: http://osercommunicationsgroup.uberflip.com/i/1104451
AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Kimberly Oser Publisher Jules Denton-Card Senior Associate Publisher Lorrie Baumann Editorial Director Anthony Socci Associate Publisher JoEllen Lowry • Jeanie Catron • Karrie Welborn Associate Editors Yasmine Brown Art Director Jonathan Schieffer Graphic Designer Caitlyn McGrath • Susan Stein Customer Service Managers Marcos Morhaim Senior Account Manager Adrian Chacon • Paul Harris • Andy Hartnett Account Managers Tara Neal Director of Operations Jay Watson • Hannah Stefanovich • Margaret Oser Show Logistics & Distribution Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2019 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy www.osercommunicationsgroup.com Lee M. Oser Founder Chain Drugstore Daily Sunday, April 28, 2019 4 High Quality & Consistent Supply: Keys to Amneal's Success Since 2002, patients, customers, physi- cians and pharmacists have trusted Amneal to consistently and reliably deliver quality pharmaceutical products. Indeed, Amneal views quality as a non- negotiable commitment – a core pillar to the compa0ny's success. It permeates every aspect of the business from R&D and manufacturing, to packaging and dis- tribution. And it explains why the compa- ny has been so successful in keeping the trust it has earned. "Everything starts with quality and supply from a customer perspective," explains Andy Boyer, Executive Vice President, Commercial Operations at Amneal. "Operations, quality and regula- tory are key functional areas that are inte- grated to allow Amneal to be successful in delivering products of high quality and at high service levels." Quality-by-design has long been a fundamental part of Amneal's operations, and teams throughout the organization push for continuous improvement. The company looks for that same quality mindset in new hires and continues to reinforce it through employee develop- ment. "Accountability runs throughout the organization," according to Joe Greer, Senior Vice President, Global Quality Management. "We embrace the concept that quality begins with each and every one of us, every day, across all roles and departments." The proof is in the numbers. Amneal has successfully completed no fewer than 70 U.S. Food and Drug Administration (FDA) inspections across its 10 manufac- turing and three distribution sites. Last year it gained an impressive 72 Abbreviated New Drug Application (ANDA) approvals (62 final and 10 ten- tative) and launched a total of 42 prod- ucts. The impressive statistics speak to a culture fully aligned with the high stan- dards set down by the FDA. Amneal's supply levels and cus- tomer service also earn praise from business partners. Amneal consistently wins top honors from customers and business partners since it launched its own label of products in 2007. Supplier awards from every major wholesaler and distributor line the shelves of its Glasgow, Kentucky distribution and sales operations facility lobby. An impressive five HDA DIANA trophies for supply chain excellence round out the selection along with recognition from the company's chain drug store partners. This year marks the opening of a third Amneal distribution center in Glasgow, Kentucky. The new site was needed to handle consolidated logistics following the company's merger with Impax, as well as a rapidly expanding pipeline. Amneal continues to focus aggres- sively on building a diversified pipeline of complex, high-value products. Its generics R&D team successfully filed 31 ANDAs in 2018, 65 percent of which were non-oral solid products, creating a pipeline of 118 filings across various dosage forms. Additionally, Amneal cur- rently has 97 generic products in devel- opment including several sterile injecta- bles. "We are committed to investing in our supply chain and are proud to consis- tently deliver one of best service levels in industry," says Boyer. "We don't plan on relenting any time soon; we continue to work with our partners in supply chain planning to ensure the trend continues." For more information, visit Outdoor Meeting Space #202 or go to www.amneal.com. Camber Introduces Generic Cialis Camber Pharmaceuticals announced the addition of Tadalafil tablets to its grow- ing portfolio of products. Tadalafil tablets are the generic version of Cialis ® from Eli Lilly Co. and is used to treat male sexual function problems. Tadalafil tablets are available in a 2.5, 5, 10 and 20mg 30-count bottles. In addition to Tadalafil, recent prod- uct launches from Camber include: omega-3 acid ethyl esters capsules - the generic version of Lovaza ® ; tolterodine tartrate ER capsules - the generic version of Detrol LA ® ; and, hydrocodone APAP tablets - the generic version of Norco ® . Two of these products, omega-3 and hydrocodone APAP, are manufactured at its newest U.S. facility, Ascent Pharmaceuticals in Central Islip, New York. The Ascent headquarters facility is a 310,000 square foot state-of-the-art research, manufacturing and distribution center complete with a high security vault for the storage of controlled sub- stances. Near future launch items for Ascent include methadone, benzonatate and methylphenidate ER. Worldwide Leaders in API Production Camber Pharmaceuticals is a fully inte- grated international pharmaceutical com- pany that maintains quality and integrity in all its products. Its parent company, Hetero Drugs of Hyderabad India, is one of the world's leading API and fin- ished dosage manu- facturers. Its 15 exclu- sive manufacturing units, including Asia's largest API facility, are vertically integrat- ed and have large-scale production capa- bilities that have enabled it to gain recog- nition as the ideal company to partner with for the launch of many first-time generics. Camber's New Headquarters Camber's new corporate headquarters and expanded warehouse space is cur- rently under construction and will more than double its inventory storage capabilities. Maintaining a consistent supply of products for cus- tomers is Camber's No. 1 goal. Camber is confident that its new warehouse, combined with significant investments in SAP and serialization, will ensure that it achieves its long-term plans for growth. Its commitment to customers is to bring the highest quality generic phar- maceuticals to the market and provide a level of excellence in service, supply and affordability. For more information, call 732.529.0430, go to www.camber pharma.com or stop by booth #534. XIL Consulting Launches Technology Solution for Retail Pharmacies: XIL Impact It's a familiar and pervasive trend: the economics of retail pharmacies is in decline. Pharmacies are contending with PBM consolidation, shrinking markets, legislation shifts – the list goes on. With such tight margins growing even tighter, every decision is crucial. A bad round of negotiations or a misguid- ed operational decision can result in staggering revenue consequences. The stakes are high. To combat these factors, retail phar- macies need access to the right data and insight. XIL leadership identified this gap in its consulting work. Without real-time data and actionable, strategy insights, retail pharmacies are left at a significant disadvantage, long-term. "We realized there was no single product addressing this need. What was available was outdated, or just a single part of a much larger roadmap," XIL Consulting Chief Executive Officer, Susan Lang, explains. "So, I decided we'd build it ourselves." Lang turned to another member of the XIL Consulting team, Senior Director of Client Innovations, Lexie Robertson, to build the radical new tool. In addition to her time in healthcare consulting, Robertson spent several years working in Silicon Valley at tech start-ups. "The goal here is to reduce the loss of market share for our subscribers. To do that, pharma- cies need four things. First, access to their own data. Second, real-time impact analysis to reference during negotiations. Third, actionable guidance to help strate- gize in the short and long-term. And finally, fourth, reporting that shows you exactly where you are, day-to-day. XIL Impact offers all of that. It's game-chang- ing." While there are products on the market that may make some of the same claims as XIL Impact, there's a few notable differences that Robertson and her team were sure to include in their build. Impact is cloud-based and acces- sible anywhere. As Robertson details, "The data goes where you do. Impact is an innovation. And it will keep evolv- ing with the market; we aim to provide everything retail pharmacies need to stay competitive and win. As that changes, so will we." In addition to the architecture, XIL Impact doesn't require half a year for implementation like some other products. It will have your data ready to go in an average of just two months. The biggest differentiator is Impact's "Optimize" feature. This tool allows pharmacy executives to enter their current and proposed payer con- tracts, and instantly develop counter- proposals during negotiations. Robertson boasts, "That means pharma- cies are suddenly negotiating from a place of strength. They see potential revenue changes in real-time and can make informed decisions." XIL Impact launches in April 2019. For more information on purchasing a subscription or about XIL Consulting, visit www.xilimpact.com or www.xil consulting.com.